Arizona State Retirement System boosted its holdings in shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) by 221.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 59,499 shares of the company’s stock after buying an additional 40,999 shares during the quarter. Arizona State Retirement System owned approximately 0.13% of Amphastar Pharmaceuticals worth $1,145,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in AMPH. Wells Fargo & Company MN grew its position in shares of Amphastar Pharmaceuticals by 156.1% in the fourth quarter. Wells Fargo & Company MN now owns 176,323 shares of the company’s stock valued at $3,392,000 after purchasing an additional 107,486 shares during the last quarter. Swiss National Bank grew its position in shares of Amphastar Pharmaceuticals by 11.8% in the fourth quarter. Swiss National Bank now owns 66,400 shares of the company’s stock valued at $1,278,000 after purchasing an additional 7,000 shares during the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Amphastar Pharmaceuticals in the fourth quarter valued at approximately $242,000. Fisher Asset Management LLC grew its position in shares of Amphastar Pharmaceuticals by 8.1% in the fourth quarter. Fisher Asset Management LLC now owns 229,277 shares of the company’s stock valued at $4,411,000 after purchasing an additional 17,094 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Amphastar Pharmaceuticals in the third quarter valued at approximately $400,000. 44.46% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ AMPH traded down $0.13 on Friday, reaching $19.01. The company had a trading volume of 157,709 shares, compared to its average volume of 261,357. The company has a market capitalization of $881.13, a price-to-earnings ratio of 50.03, a PEG ratio of 1.35 and a beta of 1.42. Amphastar Pharmaceuticals Inc has a fifty-two week low of $13.15 and a fifty-two week high of $20.45. The company has a quick ratio of 1.85, a current ratio of 2.79 and a debt-to-equity ratio of 0.12.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Monday, March 12th. The company reported $0.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.07 by $0.03. Amphastar Pharmaceuticals had a return on equity of 4.56% and a net margin of 1.88%. The business had revenue of $60.40 million during the quarter, compared to the consensus estimate of $60.62 million. During the same period in the prior year, the business posted $0.01 earnings per share. Amphastar Pharmaceuticals’s quarterly revenue was down 4.9% on a year-over-year basis. research analysts expect that Amphastar Pharmaceuticals Inc will post 0.63 earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on the company. Wells Fargo reiterated a “buy” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, March 21st. Zacks Investment Research cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 13th. BMO Capital Markets restated a “market perform” rating and set a $19.00 target price (up from $17.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 13th. Needham & Company LLC restated a “buy” rating and set a $24.00 target price (up from $23.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 13th. Finally, BidaskClub upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. Amphastar Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $21.33.
In other news, Director Richard K. Prins sold 16,598 shares of the firm’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $19.90, for a total value of $330,300.20. Following the completion of the sale, the director now directly owns 45,442 shares in the company, valued at approximately $904,295.80. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jason B. Shandell sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, March 20th. The shares were sold at an average price of $19.43, for a total value of $388,600.00. Following the completion of the sale, the insider now owns 251,372 shares of the company’s stock, valued at $4,884,157.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 84,387 shares of company stock valued at $1,659,763. Company insiders own 11.10% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Arizona State Retirement System Acquires 40,999 Shares of Amphastar Pharmaceuticals Inc (AMPH)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/08/arizona-state-retirement-system-boosts-holdings-in-amphastar-pharmaceuticals-inc-amph.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.